Now reading Entry 015 / 102 Last revised Feb 1, 2026 8 sources 4 comparisons Methodology →
A specimen of the Cognitive drawer Drawer E · Cognitive

Cerluten

Research Only

A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.

Brain cytamin · Cerebral peptides · A-5 brain peptides

Research evidence
Low

Mostly preclinical · 1 human study

Preclinical
75%
Human research
13%

Based on 8 cited sources

Numeric assessment unreviewed

A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.

This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.

Scoring context and limitations
!
Evidence Level
low
Not FDA-approved.
Research Only
Identity
Also Known As
Brain cytamin • Cerebral peptides • A-5 brain peptides

Mechanism of Action

Cerluten is a cytamin-class supplement containing peptide complexes derived from brain tissue.

Cytamin Classification

Cytamins are oral supplements in the Russian bioregulator framework:

  • Tissue-derived peptide mixtures
  • Multiple peptide fractions
  • Marketed as dietary supplements
  • Not defined single compounds

Proposed Mechanisms

  1. Neuroprotection - Claimed to support neuronal cell function
  2. Cognitive Support - Proposed effects on memory and cognition
  3. Age-Related Decline - Marketed to address cognitive aging

Important Limitations

  • NOT a defined peptide - contains complex mixture
  • Oral peptide bioavailability is generally very low
  • No Western clinical validation
  • No randomized controlled trials for cognitive outcomes
  • Not approved by any Western regulatory agency
  • NOT a treatment for dementia or cognitive disorders
Mechanism Brain peptide complex supporting neuronal function
Emerging 3 direct studies
Benefit may support cognitive function
Evidence Level
Very Low
1 Human
2 Animal
1 In Vitro
Mechanism Confidence
Established
Supported
Emerging
Evidence Level
High
Moderate
Low
Very Low
Synergistic
Compatible
Caution
Avoid

Both target brain function - Cortexin is injectable brain extract with more clinical data, Cerluten is oral cytamin supplement.

Both target brain/cognitive function - Pinealon is synthetic tripeptide, Cerluten is tissue-derived complex.

Semax

Compatible
Compatible

Both Russian nootropic peptides - Semax is defined heptapeptide with more research, Cerluten is cytamin supplement.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

8 Sources 1 Human 6 Preclinical

Key Studies Cited

Use the source links in the research discussion above to inspect the referenced records.

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare Cerluten

Related Peptides

Cognitive

Alixorexton

ALKS 2680 · ALKS-2680

An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.

See dossier
Cognitive

Cerebrolysin

FPF-1070 · N-PEP-12 · Renacenz

Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.

See dossier
Cognitive

Dihexa

PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.

See dossier
Cognitive

DSIP

Delta sleep-inducing peptide · Emideltide · WAGGDASGE

DSIP (emideltide) is a nine-amino-acid peptide investigated for sleep. Small, older intravenous studies in people with insomnia produced conflicting results; benefit for insomnia has not been established. Animal findings do not establish effects in people.

See dossier
Cognitive

N-Acetyl Selank Amidate

NA-Selank · N-Acetyl Selank · Acetyl-Selank-Amidate +1

A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.

See dossier
Cognitive

N-Acetyl Semax Amidate

NA-Semax · N-Acetyl Semax · Acetyl-Semax-Amidate +1

A chemically modified version of Semax with N-terminal acetylation and C-terminal amidation designed to enhance peptide stability. While parent Semax is approved in Russia for nootropic and neuroprotective applications, this specific modification has no independent clinical research.

See dossier

Compared With

4 comparisons

Related Content